Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-12-12
2006-12-12
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S081000, C514S082000
Reexamination Certificate
active
07148210
ABSTRACT:
The invention provides a drug combination for the treatment of diseases associated with bone metastasis. The combination provides adenosine or a derivative thereof, a bisphosphonate, and a targeting agent(s) to decrease the signs or symptoms associated with such diseases.
REFERENCES:
patent: 4291024 (1981-09-01), Turcotte
patent: 4880918 (1989-11-01), Rapaport
patent: 5049372 (1991-09-01), Rapaport
patent: 5641500 (1997-06-01), Trepel et al.
patent: 2003/0004140 (2003-01-01), Dalton et al.
patent: 2005/0130922 (2005-06-01), Altaba et al.
Bolger et al., “Strontium-89 (Metastron) Versus External Beam Radiotherapy in Patients With Painful Bone Metastases Secondary to Prostatic Cancer:Preliminary Report of a Multicenter Trial”, Seminars in Oncology 1993 20 (3) (Supplemental 2) :32-33.
Elomaa et al., “Disphosphonates for Osteolytic Metastases”, Lancet 1985 vol. 1 (8438) :1155-1156.
Fishman et al., “Adenosine and Other Low Molecular Weight Factors Released by Muscle Cells Inhibit Tumor Cell Growth1”, Cancer Research 1998 58:3181-3187.
Estrela et al., “Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays”, Nature Medicine 1995 1(1):84-88.
Fang et al., “P2-Purinergic Receptor Agonists Inhibit the Growth of Androgen-independent Prostate Carcinoma Cells”, J. Clin. Invest. 1992 89:191-196.
Galmarini et al., “Nucleotide analogues and nucleobases in cancer treatment”, Lancet Oncol. 2002 3:415-424.
Janssens and Boeynaems, “Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells”, Br. J. Pharmacol. 2001 132:536-546.
Maymon et al., “Enhancing effect of ATP on intracellular adriamycin penetration in human ovarian cancer cell lines”, Biochimica et Biophysica Acta 1994 1201:173-178.
Mure et al., “Modulation of Membrane Permeability, Cell Proliferation and Cytotoxicity of Antitumor Agents by External ATP in Mouse Tumor Cells”, Jpn J. Cancer Res. 1992 83:121-126.
Rapaport et al., “Growth Inhibition of Human Tumor Cells in Soft-Agar Cultures by Treatment with Low Levels of Adrenosine 5′-Triphosphate”, Cancer Research 1983 43:4402-4406.
Rapaport Eliezer, “Treatment of Human Tumor Cells With ADP or ATP Yields Arrest of Growth in the S Phase of the Cell Cycle”, J. Cell Physiol. 1982 114(3) :279-283.
Robinson Ralph G., M.D., “Strontium-89-Precursor Targeted Therapy for Pain Relief of Blastic Metastatic Disease”, Cancer 1993 72:3433-3435.
Schroder and Rapaport, “Retinoic Acid Alters Subcellular Compartmentalization of ATP Pools in 3T3 Cells but Not in HeLa Cells”, J. Cell Physiol. 1984 120(2) :204-210.
van Holten-Verzantvoort et al., “Reduced Morbidity from Skeletal Metastases in Breast Cancer Patients During Long-Term Bisphosphonate (APD) Treatment”, Lancet 1987 2(8566) 983-.
von Albertini et al., “Extracellular ATP and ADP Activate Transcription Factor NF-KB and Induce Endothelial Cell Apoptosis”, Biochem. Biophys. Res. Commun. 1998 248 (3) :822-829.
von Albertini et al., “Adenosine Nucleotides Induce E-Selectin Expression in Porcine Endothelial Cells”, Transplant Proc. 1997 29(1-2) :1062.
Licata & Tyrrell P.C.
Pryor Alton
Trustees of Dartmouth College
LandOfFree
Method of treating bone metastasis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating bone metastasis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating bone metastasis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3683506